Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
02:30:00 2026-09-18 am EDT
|
5-day change | 1st Jan Change | ||
| 5,968.00 JPY | +0.37% |
|
+5.33% | +23.43% |
| Sep. 18 | Dr. Reddy's, Takeda Sign Deal to Distribute QDENGA Dengue Vaccine in India | MT |
| Sep. 18 | Dr. Reddy's Enters Agreement to Bring Takeda's Dengue Vaccine to India | MT |
| Market Cap | 9,529B 60.71B 52.94B 49.99B 45.39B 85.04B 5,825B 85.4B 599B 231B 2,962B 228B 223B | P/E 2027 * |
47.3x | P/E 2028 * | 30x |
|---|---|---|---|---|---|
| Enterprise Value | 13,436B 85.6B 74.64B 70.48B 64B 120B 8,213B 120B 844B 326B 4,176B 322B 314B | EV / Sales 2027 * |
2.86x | EV / Sales 2028 * | 2.77x |
| Free-Float |
99.25% | Yield 2027 * |
3.42% | Yield 2028 * | 3.49% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
OTC Markets
| TKPHF | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Tradegate
| TKD | Real-time | |
|
Deutsche Boerse AG
| TKD | Delayed | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.37% | ||
| 1 week | +5.33% | ||
| Current month | +3.52% | ||
| 1 month | +3.45% | ||
| 3 months | +20.96% | ||
| 6 months | +3.47% | ||
| Current year | +23.43% |
| 1 week | 5,640 |  | 6,012 |
| 1 month | 5,557 | | 6,012 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2024-12-31 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
Steven Gillis
BRD | Director/Board Member | 73 | 2018-12-31 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 2024-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/14/26 | Sell | Executive/Senior Manager | -34,535 | 0.0022% | ||
| 9/2/26 | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 8/19/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.37% | +5.33% | +33.27% | +23.59% | 60.71B | |
| +0.04% | +3.34% | +53.32% | +100.52% | 1,028B | |
| -0.09% | +1.66% | +53.24% | +66.45% | 651B | |
| -0.02% | +2.66% | +18.65% | +71.97% | 466B | |
| -1.22% | +3.66% | +34.59% | +38.81% | 346B | |
| -0.79% | +2.73% | +17.73% | +25.11% | 266B | |
| +0.58% | +6.76% | +10.58% | +17.75% | 259B | |
| +1.55% | +2.20% | +35.12% | +45.91% | 208B | |
| +0.79% | +1.84% | -27.55% | -56.48% | 191B | |
| -0.52% | +4.45% | +31.57% | +98.11% | 186B | |
| Average | +0.07% | +3.46% | +26.05% | +43.17% | 366.24B | |
| Weighted average by Cap. | -0.03% | +3.13% | +34.82% | +60.97% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,701B 29.95B 26.11B 24.66B 22.39B 41.95B 2,874B 42.13B 295B 114B 1,461B 112B 110B | 4,782B 30.46B 26.57B 25.08B 22.78B 42.68B 2,923B 42.85B 300B 116B 1,486B 114B 112B |
| Net income | 196B 1.25B 1.09B 1.03B 936M 1.75B 120B 1.76B 12.35B 4.76B 61.07B 4.7B 4.6B | 323B 2.06B 1.79B 1.69B 1.54B 2.88B 197B 2.89B 20.28B 7.82B 100B 7.72B 7.55B |
| Net Debt | 3,907B 24.89B 21.7B 20.49B 18.61B 34.86B 2,388B 35.01B 245B 94.72B 1,214B 93.49B 91.41B | 3,702B 23.59B 20.57B 19.42B 17.63B 33.04B 2,263B 33.18B 233B 89.77B 1,151B 88.6B 86.63B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-18 | ¥5,968.00 | +0.37% | 6,517,000 |
| 26-09-17 | ¥5,946.00 | +1.69% | 4,687,800 |
| 26-09-16 | ¥5,847.00 | 0.00% | 3,811,500 |
| 26-09-15 | ¥5,847.00 | +1.92% | 4,665,400 |
| 26-09-14 | ¥5,737.00 | +1.25% | 2,846,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
